Heart transplantation in cardiac amyloidosis

Heart Failure Reviews

Volumn 22, Issue 3, 2017, Pages 317-327

  Sousa, Matthew ^a   Monohan, Gregory ^a   Rajagopalan, Navin ^a   Grigorian, Alla ^a   Guglin, Maya ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Cardiac amyloidosis; Heart failure; Heart transplantation

Indexed keywords

AL AMYLOIDOSIS; ATTR AMYLOIDOSIS; CARDIOVASCULAR MORTALITY; CLINICAL EFFECTIVENESS; HEART AMYLOIDOSIS; HEART TRANSPLANTATION; HUMAN; LONG TERM SURVIVAL; MORTALITY RATE; OUTCOME ASSESSMENT; PROGNOSIS; REVIEW; SURVIVAL RATE; SURVIVAL TIME; AMYLOIDOSIS; CARDIOMYOPATHY; COMPLICATION; GLOBAL HEALTH; HEART FAILURE; MORBIDITY; TRENDS;

AMYLOIDOSIS; CARDIOMYOPATHIES; GLOBAL HEALTH; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; MORBIDITY;

EID: 85014668556     PISSN: 13824147     EISSN: 15737322     Source Type: Journal    
DOI: 10.1007/s10741-017-9601-z     Document Type: Review

References (86)

1. Falk RH, Alexander KM, Liao R, Dorbala S (2016) AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy. J Am Coll Cardiol 68:1323–1341
2. Coelho T, Adams D, Silva A et al (2013) Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 369:819–829
3. Merlini G, Bellotti V (2003) Molecular mechanisms of amyloidosis. N Engl J Med 349:583–596
4. Franklin EC, Lowenstein J, Bigelow B, Meltzer M (1964) Heavy chain disease—a new disorder of serum gamma-globulins: report of the first case. Am J Med 37:332–350
5. Guan J, Mishra S, Shi J et al (2013) Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity. Basic Res Cardiol 108:378
6. Maleszewski JJ (2015) Cardiac amyloidosis: pathology, nomenclature, and typing. Cardiovascular pathology: the official journal of the Society for Cardiovascular Pathology 24:343–350
7. Yunokawa K, Hagiyama Y, Mochizuki Y, Tanaka N, Ochi M (2007) Hypertrophic spinal pachymeningitis associated with heavy-chain disease. Case report. Journal of neurosurgery Spine 7:459–462
8. Desport E, Bridoux F, Sirac C et al (2012) Al amyloidosis. Orphanet journal of rare diseases 7:54
9. Lee MT, Parwani A, Humphrey R, Hamilton RG, Myers DI, Detrick B (2008) Gamma heavy chain disease in a patient with diabetes and chronic renal insufficiency: diagnostic assessment of the heavy chain fragment. J Clin Lab Anal 22:146–150
10. Gertz MA, Comenzo R, Falk RH et al (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 79:319–328
11. Patel KS, Hawkins PN (2015) Cardiac amyloidosis: where are we today? J Intern Med 278:126–144
12. Kim SK, Park IK, Park BH et al (2005) A case report: isolated a heavy chain monoclonal gammopathy in a patient with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin change syndrome. International journal of clinical practice Supplement 26-30
13. Merlini G, Palladini G (2013) Light chain amyloidosis: the heart of the problem. Haematologica 98:1492–1495
14. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR 3rd, Dogan A (2009) Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 114:4957–4959
15. Brambilla F, Lavatelli F, Di Silvestre D et al (2012) Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood 119:1844–1847
16. Wester SM, Banks PM, Li CY (1982) The histopathology of gamma heavy-chain disease. Am J Clin Pathol 78:427–436
17. Wechalekar AD, Schonland SO, Kastritis E et al (2013) A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 121:3420–3427
18. Kumar SK, Dispenzieri A, Lacy MQ et al (2011) Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. Am J Hematol 86:251–255
19. Dispenzieri A, Kyle RA, Lacy MQ et al (2004) Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood 103:3960–3963
20. Dubrey SW, Cha K, Anderson J et al (1998) The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM: monthly journal of the Association of Physicians 91:141–157
21. Gray Gilstrap L, Niehaus E, Malhotra R et al (2014) Predictors of survival to orthotopic heart transplant in patients with light chain amyloidosis. The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation 33:149–156
22. Sperry BW, Ikram A, Hachamovitch R et al (2016) Efficacy of chemotherapy for light-chain amyloidosis in patients presenting with symptomatic heart failure. J Am Coll Cardiol 67:2941–2948
23. Potena L, Quarta CC, Grigioni F, Rapezzi C (2014) Prognostic stratification and treatment of cardiac light chain amyloidosis: a narrow path in the jungle. The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation 33:136–138
24. Cordes S, Dispenzieri A, Lacy MQ et al (2012) Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis. Cancer 118:6105–6109
25. Gertz MA, Lacy MQ, Dispenzieri A et al (2002) Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med 113:549–555
26. Sanchorawala V (2012) Role of high-dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis. American journal of blood research 2:9–17
27. Estep JD, Bhimaraj A, Cordero-Reyes AM, Bruckner B, Loebe M, Torre-Amione G (2012) Heart transplantation and end-stage cardiac amyloidosis: a review and approach to evaluation and management. Methodist DeBakey cardiovascular journal 8:8–16
28. Bradshaw SH, Veinot JP (2012) Cardiac amyloidosis: what are the indications for transplant? Curr Opin Cardiol 27:143–147
29. Maurer MS, Hanna M, Grogan M et al (2016) Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol 68:161–172
30. Benson MD (2000) Amyloidosis. The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 5345–5378
31. Ando Y, Coelho T, Berk JL et al (2013) Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet journal of rare diseases 8:31
32. Yamashita T, Hamidi Asl K, Yazaki M, Benson MD (2005) A prospective evaluation of the transthyretin Ile122 allele frequency in an African-American population. Amyloid: the international journal of experimental and clinical investigation: the official journal of the International Society of Amyloidosis 12:127–130
33. Buxbaum J, Alexander A, Koziol J, Tagoe C, Fox E, Kitzman D (2010) Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies. Am Heart J 159:864–870
34. Rapezzi C, Quarta CC, Riva L et al (2010) Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol 7:398–408
35. Suhr OB, Larsson M, Ericzon BG, Wilczek HE (2016) Survival after transplantation in patients with mutations other than Val30Met: extracts from the FAP world transplant registry. Transplantation 100:373–381
36. Arruda-Olson AM, Zeldenrust SR, Dispenzieri A et al (2013) Genotype, echocardiography, and survival in familial transthyretin amyloidosis. Amyloid: the international journal of experimental and clinical investigation: the official journal of the International Society of Amyloidosis 20:263–268
37. Grogan M, Scott CG, Kyle RA et al (2016) Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol 68:1014–1020
38. Castano A, Drachman BM, Judge D, Maurer MS (2015) Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev 20:163–178
39. Rowczenio D, Dogan A, Theis JD et al (2011) Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I. Am J Pathol 179:1978–1987
40. Selvanayagam JB, Hawkins PN, Paul B, Myerson SG, Neubauer S (2007) Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol 50:2101–2110
41. Mehra MR, Canter CE, Hannan MM et al (2016) The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation 35:1–23
42. DePasquale EC, Nasir K, Jacoby DL (2012) Outcomes of adults with restrictive cardiomyopathy after heart transplantation. The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation 31:1269–1275
43. Dubrey SW, Burke MM, Hawkins PN, Banner NR (2004) Cardiac transplantation for amyloid heart disease: the United Kingdom experience. The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation 23:1142–1153
44. Hall R, Hawkins PN (1994) Cardiac transplantation for AL amyloidosis. BMJ (Clinical research ed) 309:1135–1137
45. Conner R, Hosenpud JD, Norman DJ, Pantely GA, Cobanoglu A, Starr A (1988) Heart transplantation for cardiac amyloidosis: successful one-year outcome despite recurrence of the disease. The Journal of heart transplantation 7:165–167
46. Kpodonu J, Massad MG, Caines A, Geha AS (2005) Outcome of heart transplantation in patients with amyloid cardiomyopathy. The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation 24:1763–1765
47. Kristen AV, Brokbals E, Aus dem Siepen F et al (2016) Cardiac amyloid load: a prognostic and predictive biomarker in patients with light-chain amyloidosis. J Am Coll Cardiol 68:13–24
48. Dey BR, Chung SS, Spitzer TR et al (2010) Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure. Transplantation 90:905–911
49. Lacy MQ, Dispenzieri A, Hayman SR et al (2008) Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy. The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation 27:823–829
50. Hsich EM, Rogers JG, McNamara DM et al. (2016) Does survival on the heart transplant waiting list depend on the underlying heart disease? JACC Heart failure
51. Alloni A, Pellegrini C, Ragni T et al (2004) Heart transplantation in patients with amyloidosis: single-center experience. Transplant Proc 36:643–644
52. Hosenpud JD, DeMarco T, Frazier OH et al (1991) Progression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation. Follow-up results of a multicenter survey. Circulation 84:III338–III343
53. Gillmore JD, Goodman HJ, Lachmann HJ et al (2006) Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood 107:1227–1229
54. Rosenbaum AN, Edwards BS (2015) Current indications, strategies, and outcomes with cardiac transplantation for cardiac amyloidosis and sarcoidosis. Curr Opin Organ Transplant 20:584–592
55. Colvin M, Smith JM, Skeans MA et al (2016) Heart. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg 16(Suppl 2):115–140
56. Davis MK, Kale P, Liedtke M et al (2015) Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg 15:650–658
57. Kristen AV, Sack FU, Schonland SO et al (2009) Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis. Eur J Heart Fail 11:1014–1020
58. Grogan M, Gertz M, McCurdy A et al (2016) Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: the Mayo Clinic experience. World J Transplant 6:380–388
59. Varr BC, Liedtke M, Arai S, Lafayette RA, Schrier SL, Witteles RM (2012) Heart transplantation and cardiac amyloidosis: approach to screening and novel management strategies. The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation 31:325–331
60. Davis MK, Lee PH, Witteles RM (2015) Changing outcomes after heart transplantation in patients with amyloid cardiomyopathy. The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation 34:658–666
61. Baumgratz JF, Vila JH, Guilhen CJ et al (2009) Heart transplantation in primary amyloidosis. Rev Bras Cir Cardiovasc 24:409–412
62. Perz JB, Kristen AV, Rahemtulla A et al (2006) Long-term survival in a patient with AL amyloidosis after cardiac transplantation followed by autologous stem cell transplantation. Clinical research in cardiology: official journal of the German Cardiac Society 95:671–674
63. Maurer MS, Raina A, Hesdorffer C et al (2007) Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure. Transplantation 83:539–545
64. Sack FU, Kristen A, Goldschmidt H et al (2008) Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis. European journal of cardio-thoracic surgery: official journal of the European Association for Cardio-thoracic Surgery 33:257–262
65. Gibbs SD, Sattianayagam PT, Hawkins PN, Gillmore JD (2009) Cardiac transplantation should be considered in selected patients with either AL or hereditary forms of amyloidosis: the UK National Amyloidosis Centre experience. Intern Med J 39:786–787 author reply 787-8
66. Luo JM, Chou NK, Chi NH et al (2010) Heart transplantation in patients with amyloidosis. Transplant Proc 42:927–929
67. Mignot A, Varnous S, Redonnet M et al (2008) Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients. Archives of cardiovascular diseases 101:523–532
68. Roig E, Almenar L, Gonzalez-Vilchez F et al (2009) Outcomes of heart transplantation for cardiac amyloidosis: subanalysis of the Spanish registry for heart transplantation. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg 9:1414–1419
69. Sattianayagam PT, Gibbs SD, Pinney JH et al (2010) Solid organ transplantation in AL amyloidosis. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg 10:2124–2131
70. Te HS, Anderson AS, Millis JM, Jeevanandam V, Jensen DM (2008) Current state of combined heart-liver transplantation in the United States. The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation 27:753–759
71. Holmgren G, Steen L, Ekstedt J et al (1991) Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet 40:242–246
72. Rela M, Muiesan P, Heaton ND et al (1995) Orthotopic liver transplantation for hepatic-based metabolic disorders. Transplant international: official journal of the European Society for Organ Transplantation 8:41–44
73. Wilczek HE, Larsson M, Ericzon BG (2011) Long-term data from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR). Amyloid: the international journal of experimental and clinical investigation: the official journal of the International Society of Amyloidosis 18(Suppl 1):193–195
74. Ericzon BG, Wilczek HE, Larsson M et al (2015) Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation 99:1847–1854
75. Cannon RM, Hughes MG, Jones CM, Eng M, Marvin MR (2012) A review of the United States experience with combined heart-liver transplantation. Transplant international: official journal of the European Society for Organ Transplantation 25:1223–1228
76. Careddu L, Zanfi C, Pantaleo A et al (2015) Combined heart-liver transplantation: a single-center experience. Transplant international: official journal of the European Society for Organ Transplantation 28:828–834
77. Coelho T, Maia LF, da Silva AM et al (2013) Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol 260:2802–2814
78. Ammirati E, Marziliano N, Vittori C et al (2012) The first Caucasian patient with p.Val122Ile mutated-transthyretin cardiac amyloidosis treated with isolated heart transplantation. Amyloid: the international journal of experimental and clinical investigation: the official journal of the International Society of Amyloidosis 19:113–117
79. Thenappan T, Fedson S, Rich J et al (2014) Isolated heart transplantation for familial transthyretin (TTR) V122I cardiac amyloidosis. Amyloid: the international journal of experimental and clinical investigation: the official journal of the International Society of Amyloidosis 21:120–123
80. Hamour IM, Lachmann HJ, Goodman HJ et al (2008) Heart transplantation for homozygous familial transthyretin (TTR) V122I cardiac amyloidosis. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg 8:1056–1059
81. Arpesella G, Chiappini B, Marinelli G et al (2003) Combined heart and liver transplantation for familial amyloidotic polyneuropathy. J Thorac Cardiovasc Surg 125:1165–1166
82. Grazi GL, Cescon M, Salvi F et al (2003) Combined heart and liver transplantation for familial amyloidotic neuropathy: considerations from the hepatic point of view. Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 9:986–992
83. Nardo B, Beltempo P, Bertelli R et al (2004) Combined heart and liver transplantation in four adults with familial amyloidosis: experience of a single center. Transplant Proc 36:645–647
84. Raichlin E, Daly RC, Rosen CB et al (2009) Combined heart and liver transplantation: a single-center experience. Transplantation 88:219–225
85. Barreiros AP, Post F, Hoppe-Lotichius M et al (2010) Liver transplantation and combined liver-heart transplantation in patients with familial amyloid polyneuropathy: a single-center experience. Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 16:314–323
86. Nelson LM, Penninga L, Sander K et al (2013) Long-term outcome in patients treated with combined heart and liver transplantation for familial amyloidotic cardiomyopathy. Clin Transpl 27:203–209